Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis.
BACKGROUND
We assessed the efficacy of continuation treatment with antidepressants in a meta-analysis of relapse prevention studies in the five principal anxiety disorders, to explore the benefit of continuation treatment in each disorder, and their relative efficacy across these disorders.


METHODS
Double-blind placebo-controlled studies with relapse prevention designs in Panic Disorder, Generalized Anxiety Disorder, Social Phobia, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder were identified in a systematic literature search. The primary efficacy comparison was relapse rates between active and placebo arms calculated as odds ratios (ORs) using Review Manager version 5.0. Relapse data were also used to calculate relative risk (RR), risk difference (RD) and number needed to treat (NNT).


RESULTS
Twenty-two relapse prevention trials were identified for these 5 disorders. Continuation antidepressant treatment produced robust treatment effects for each disorder, however the magnitude varied by indication. The greatest treatment effect was noted for GAD (pooled OR 0.20), whereas the pooled ORs for PD and OCD were for almost 2-fold higher (0.35 and 0.38 respectively). RR, RD and NNT showed similar statistically significant trends.


CONCLUSIONS
This study cannot identify an optimal duration of therapy. This analysis only examined studies testing monoamine reuptake inhibiting antidepressants, and therefore these results might not be generalizable to other classes of antianxiety agents.


CONCLUSIONS
This meta-analysis underscores the importance of continuation treatment following acute response in all 5 anxiety disorders, however the relative efficacy of continuation antidepressant treatment appears to vary by disorder.
Donovan
Mary Rocco
MR
The Graduate Center, The City University of New York, NY, USA.
Glue
Paul
P
Kolluri
Sheela
S
Emir
Birol
B
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000523:psychology; D016584:Panic Disorder / Q000188:drug therapy / Q000523:psychology; D010552:Personality Assessment; D010698:Phobic Disorders / Q000188:drug therapy / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy / Q000523:psychology; D016896:Treatment Outcome
D000928:Antidepressive Agents